drug_type
RELEVANT_DRUG
intervention_type
Biological (adoptive T-cell therapy)
drug_description
Adoptive T-cell therapy from healthy CMV-seropositive donors; HLA-matched CMV-specific T cells recognize CMV antigens on glioblastoma cells and kill them via T-cell cytotoxicity and cytokine release.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
TCR SELECTED T CELLS
drug_class
Unedited cells
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic CMV-specific T cells expanded from seropositive donors and HLA-matched to the patient recognize CMV peptide–HLA complexes on glioblastoma cells via their native TCRs, leading to targeted cytotoxicity (perforin/granzyme) and cytokine-mediated antitumor activity.
drug_name
Allogeneic cytomegalovirus (CMV)-specific T cells (CYT-101)
nct_id_drug_ref
NCT06157541